Advice

in the absence of a submission from the holder of the marketing authorisation:

glycopyrronium / formoterol fumarate dihydrate (Bevespi Aerosphere®) is not recommended for use within NHSScotland.

Indication under review: Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice621KB (PDF)

Download

Medicine details

Medicine name:
glycopyrronium/formoterol fumarate dihydrate (Bevespi Aerosphere)
SMC ID:
SMC2377
Indication:

Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.

Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Respiratory system
Submission type
Non submission
Status
Not recommended
Date advice published
10 May 2021